Physician profile
Thomas D Conley
NPI 1053384974
$11,961.73
in general payments reported to CMS, 2019-2025
32 companies · $2,745 in 2025
The $2,745 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $538 · 2021: $1,044 · 2022: $1,870 · 2023: $1,652 · 2024: $2,905 · 2025: $2,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,282 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,281.60 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $3,181.27 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $2,761.14 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,374.97 | 2019-2025 | |
| Boston Scientific Corporation | $1,143.27 | 2019-2025 | Crossboss, Stingray, Fighter |
| Abbott Laboratories | $777.79 | 2019-2025 | Coroflow, Pressurewire, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $504.82 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $265.18 | 2019-2024 | Farxiga, Wainua |
| Pfizer INC. | $238.44 | 2019-2025 | |
| Asahi Intecc USA, INC. | $197.11 | 2022-2023 | Asahi Ptca Guide Wire |
| Angiodynamics, INC. | $187.50 | 2025 | Alphavac |
| Merck Sharp & Dohme LLC | $178.19 | 2021-2025 | Verquvo |
| Biotronik INC. | $163.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $157.80 | 2019-2023 | Xarelto |
| Amgen INC. | $115.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.76 | 2020-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $104.26 | 2020-2022 | |
| Cardiva Medical, INC. | $76.26 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Sanofi-Aventis U.S. LLC | $70.64 | 2019 | |
| Baxter Healthcare | $51.17 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.44 | 2019-2024 | Lifevest |
| Inari Medical, INC. | $41.87 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Philips North America LLC | $36.45 | 2024 | (Bq9) Coronary Ivus |
| Novo Nordisk INC | $30.49 | 2024 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $21.70 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.43 | 2024 | |
| Irhythm Technologies, INC. | $17.96 | 2024 | Zio At Patch |
| Esperion Therapeutics, INC. | $17.47 | 2021 | |
| Elutia, INC. | $16.46 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Amarin Pharma, INC. | $14.62 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.99 | 2020 | |
| Astellas Pharma US INC | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.